SAIPARENTSai Parenterals Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SAIPARENT — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 435.1% YoY
- • Profit growth: 1527.3% YoY
- • ROE: 17.6%
- • MACD: fresh bullish crossover
- • Sector momentum: sector +6.2% (1m)
- • Max drawdown (1y): 17%
Bull case
- • Revenue growth: 435.1% YoY
- • Profit growth: 1527.3% YoY
- • ROE: 17.6%
- • MACD: fresh bullish crossover
Bear case
- • ROCE: 10.0%
- • Valuation vs sector: P/E 117.3 vs sector 40.5
- • Price vs EMA21: below
- • Price vs SMA50: below
Key risks
- • Momentum is fading versus the broader market
- • ROCE: 10.0%
- • Valuation vs sector: P/E 117.3 vs sector 40.5
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹18.20). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.